WIB-San Diego: CAR-T – From Breakthrough to Blueprint & What Comes Next

Our recent discussion on cell and gene therapy focused on CAR T-cell therapy (Chimeric Antigen Receptor T-cell therapy), a specialized cancer treatment that genetically modifies a patient’s own white blood cells (T cells) in a lab to recognize and attack cancer cells. Our expert panel consisted of Laura Shawver (RA Ventures), Kathy Hassig (Syneos Health), Michelle Duquette (Invetech), Jenny Hamilton (Azalea Therapeutics), Caitlin Castello, MD (UC San Diego Health), and Vicki Plaks (Johnson & Johnson), who shared the most recent discoveries and key challenges shaping the field. They highlighted that, just a few decades ago, cell and gene therapy did not exist, and that it took nearly 20 years of research and innovation to bring these treatments into clinical practice. CAR-T cell therapy is now recognized as transformational, offering some patients the possibility of a cure rather than long-term disease management. With seven FDA-approved CAR-T therapies available, speakers emphasized both the progress made and the complexity of these treatments.

Panelists also discussed the advantages of these therapies, including treatment-free intervals and reduced long-term toxicity compared to traditional approaches. At the same time, they addressed key barriers to access, noting that current manufacturing processes are highly complex, involve many manual steps, and introduce variability. Proposed solutions included automating and streamlining production and bringing manufacturing closer to patients to improve accessibility. Another important topic was the emerging in vivo approach, seen as the future of cell and gene therapy, where the body can manufacture its own therapeutic cells. Approaches under investigation include non-viral delivery systems such as lipid nanoparticles, as well as viral-based strategies. The panel also highlighted how researchers and clinicians rely heavily on industry partners, medical science liaisons (MSLs), and academic centers to communicate advances and expand patient access across the U.S. 

Big thanks to our volunteers for organizing a highly successful panel and to our panelists for the insightful discussion, marked by diverse perspectives and deep expertise.

Submitted by Deisy Corredor